We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
Amminger, GP, Schafer, MR, Papageorgiou, K, Klier, CM, Cotton, SM, Harrigan, SM, Mackinnon, A, Mcgorry, PD, Berger, GE (2010). Long-chain {omega}-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry67, 146–154.CrossRefGoogle ScholarPubMed
Bloch, MH, Hannestad, J (2012). Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Molecular Psychiatry17, 1272–1282.CrossRefGoogle ScholarPubMed
Frances, A (2010). Opening pandora's box: The 19 worst suggestions for DSM-5. Psychiatric Times, p. 27.Google Scholar
Gillies, D, Sinn, J, Lad, S, Leach, M, Ross, M (2012). Polyunsaturated fatty acids (PUFA) supplements for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database of Systematic Reviews7, CD007986.CrossRefGoogle Scholar
Hooper, L, Thompson, RL, Harrison, RA, Summerbell, CD, Ness, AR, Moore, HJ, Worthington, HV, Durrington, PN, Higgins, JP, Capps, NE (2006). Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. British Medical Journal332, 752–760.CrossRefGoogle ScholarPubMed
Marshall, M, Rathbone, J (2011). Early intervention for psychosis. Cochrane Database of Systematic Reviews6, CD004718.Google Scholar
Mcfarlane, WR, Cook, WL, Downing, D, Verdi, MB, Woodberry, KA, Ruff, A (2010). Portland identification and early referral: a community-based system for identifying and treating youths at high risk of psychosis. Psychiatric Services61, 512–515.CrossRefGoogle ScholarPubMed
Moynihan, R, Heath, I, Henry, D (2002). Selling sickness: the pharmaceutical industry and disease mongering. British Medical Journal324, 886–891.CrossRefGoogle ScholarPubMed
Nieman, DH, Rike, WH, Becker, HE, Dingemans, PM, Van Amelsvoort, TA, De Haan, L, Van der Gaag, M, Denys, DA, Linszen, DH (2009). Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis. International Clinical Psychopharmacology24, 223–228.CrossRefGoogle ScholarPubMed
O'connor, K (2013). Research in young people at ultra-high risk for psychosis: a review of the current evidence. Irish Journal of Psychological Medicine30, 77–89.CrossRefGoogle ScholarPubMed
Sydenham, E, Dangour, A, Lim, W (2012). Fish oils for the prevention of dementia in older people. Cochrane Database of Systematic Reviews6, CD005379.Google Scholar
Warner, R (2005). Problems with early and very early intervention in psychosis. The British Journal of Psychiatry187, s104–s107.CrossRefGoogle Scholar
Whitely, M (2012). Whitely slams Patrick McGorry for disease mongering. Online video clip. Youtube, 6 October 2012. Accessed 26 June 2013.Google Scholar
Yung, AR, Phillips, LJ, Yuen, HP, Francey, SM, Mcfarlane, CA, Hallgren, M, Mcgorry, PD (2003). Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophrenia Research60, 21–32.CrossRefGoogle ScholarPubMed
Yung, AR, Yuen, HP, Berger, G, Francey, S, Hung, T-C, Nelson, B, Phillips, L, Mcgorry, P (2007). Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?Schizophrenia Bulletin33, 673–681.CrossRefGoogle ScholarPubMed